
Contents
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Haematological disorders Haematological disorders
-
Anaemia Anaemia
-
Diagnosis and evaluation Diagnosis and evaluation
-
-
Thrombocytopenia Thrombocytopenia
-
Diagnosis and evaluation Diagnosis and evaluation
-
Treatment Treatment
-
-
Thrombotic thrombocytopenic purpura Thrombotic thrombocytopenic purpura
-
Neutropenia Neutropenia
-
Diagnosis and evaluation Diagnosis and evaluation
-
Treatment Treatment
-
-
Coagulation disorders Coagulation disorders
-
-
Persistent generalized lymphadenopathy Persistent generalized lymphadenopathy
-
-
-
-
-
-
-
-
51 HIV: reticulo-endothelial disorders
-
Published:September 2010
Cite
Haematological disorders
Common haematological abnormalities may lead to consideration of HIV as the cause. Direct effect of HIV itself or 2° to concurrent infection, malignancy, and therapeutic agents. Common findings are ↓ haemopoiesis, altered coagulation, and immune-mediated cytopenias with ↓ bone marrow cellularity and dysplasia.
Anaemia
Most common form of cytopenia and an independent prognostic factor. Usually due to ↓ erythropoiesis, but other mechanisms (e.g. infection, drug toxicity, malignancy, dietary deficiencies, alcohol abuse, blood loss) may contribute. Chronic anaemia causes fatigue, exertional dyspnoea, and a hyperdynamic state which, if severe, may lead to angina, congestive cardiac failure, and confusion.
Diagnosis and evaluation
Examine and test for iron, vitamin B12, and folate deficiencies, haemolysis, and blood loss according to red cell indices. Eliminate possible causes by excluding infection and malignancy and reviewing drug therapy. Bone marrow examination may be required.
HIV-related: normocytic normochromic anaemia ↑ in frequency and severity as HIV progresses. May be a direct effect of HIV on bone marrow progenitor cells, ↓ erythropoietin production, and ↑ cytokines (inhibit haemopoiesis). Improves or normalizes with HAART provided that drug effects do not supervene.
Drug toxicity
Macrocytosis and normal haemoglobin—typical with zidovudine (AZT).
Macrocytic anaemia—caused by AZT and stavudine. AZT exerts broader myelosuppressive effects, more frequent in patients receiving higher doses (in ~1% receiving 500mg a day) and those with advanced disease. Anaemia may require blood transfusion following discontinuation of AZT. In patients with a low level of endogenous erythropoietin (<500IU/L), recombinant human erythropoietin may resolve anaemia, thereby ↓ need for transfusion.
Normocytic normochromic anaemia—associated with normal or ↓ reticulocyte count, 2° to bone marrow suppression. Causes include anaemia of chronic infection and drugs (e.g. ganciclovir, co-trimoxazole, amphotericin, and interferons).
Haemolytic anaemia—features are macrocytosis, ↓ haptoglobin, and ↑ lactic dehydrogenase, indirect bilirubin, and reticulocyte count. Common causes include drugs, e.g. dapsone (with methaemoglobinaemia), ribavirin, and primaquin. Glucose-6-phosphate dehydrogenase (G6PD) deficiency predisposes to dapsone and primaquin haemolysis. Autoimmune haemolytic anaemia (AIHA) with positive Coombs’ test also occurs.
Bone marrow infiltration (usually causes pancytopenia)
Opportunistic infection (OI)—most commonly Mycobaterium avium complex (also tuberculosis and cytomegalovirus).
Tumours—lymphoma and rarely Kaposi’s sarcoma.
B19 parvovirus infects erythroid precursors. In immune deficiency persistent infection may result in severe chronic normocytic normochromic anaemia. Diagnosed by detecting B19 parvovirus antibodies and DNA (by polymerase chain reaction) in serum and/or bone marrow. Responds well to high-dose IV immunoglobulins (0.4g/kg/day) which contain parvovirus antibodies, but may require repeated blood transfusions.
Thrombocytopenia
Occurs in up to 30%. May be result of drug toxicity, immune and non-immune destruction, or defective platelet production. Commonly an isolated haematological abnormality with ↑ levels of antiplatelet immunoglobulin. HIV-related immune thrombocytopenia is frequent early finding, tending to deteriorate as HIV progresses. Results from clearance of immunoglobulin-coated platelets by reticulo-endothelial system.
Diagnosis and evaluation
Exclude underlying causes, e.g. drug toxicity, liver disease, alcoholism, and lymphoma. In their absence the presence of normal or ↑ megakaryocytes on bone marrow examination is sufficient to diagnose HIV-induced thrombocytopenia.
Treatment
Mild and asymptomatic—HAART, switch/discontinue implicated drugs.
Symptomatic or before surgical procedures—IV immunoglobulins, steroids, and HAART.
Substantial bleeding—packed red cells and platelet transfusion.
Thrombotic thrombocytopenic purpura
Rare, of unknown aetiology, usually seen in early stages of HIV infection. Characterized by hyaline microvascular deposits. Clinical features include fever, renal impairment, neurological deficit, and microangiopathic haemolytic anaemia. Mortality rate ~65% without treatment. However, good response to plasmapheresis, steroids, HAART, and antiplatelets (e.g. aspirin).
Neutropenia
HIV directly implicated, especially in advanced stages. More commonly due to drug toxicity, associated infection, and bone marrow infiltration. Risk of bacterial infection ↑ significantly when absolute neutrophil count <500cells/μL. Drugs causing neutropenia include AZT, ganciclovir, co-trimoxazole, pentamidine, α-interferon, and chemotherapeutic agents.
Diagnosis and evaluation
Careful review of medication. Withdraw offending drug(s) if absolute neutrophil count <500cells/μL. If cause uncertain, consider bone marrow examination.
Treatment
HAART: variable response.
Granulocyte colony-stimulating factor:
HIV-induced
drug-induced (if implicated drug cannot be reduced or stopped).
Coagulation disorders
↑ risk of thrombotic disease associated with low CD4 counts, OIs, neoplasms, and HIV-associated autoimmune disorders.
High inflammatory state; increased D-dimer and cytokines are proposed factors in advanced disease.
Lupus anticoagulant may be detected with thromboembolic disease.
↓ levels of active protein S frequently found, although not associated with immune suppression.
Contributing prothrombotic factors include ↓ plasminogen activator inhibitor level, abnormal platelet aggregation, and ↑ von Willebrand factor.
Persistent generalized lymphadenopathy
Generalized lymphadenopathy involving ≥2 extra-inguinal sites persisting for more than 3 months. Of no prognostic significance, but other causes of generalized lymphadenopathy should be excluded. Occurs in up to 70% of patients within 1 year of seroconversion but may coexist with other manifestations of HIV infection. Lymph nodes usually symmetrical, >1cm in size, rubbery, and non-tender. May be accompanied by hepatosplenomegaly. Mediastinal lymphadenopathy usually has other causes.
Persistent generalized lymphadenopathy
Bacterial infections (including mycobacteria)
2° syphilis
Lymphoma
Histoplasmosis
Multicentric Castleman’s disease
Month: | Total Views: |
---|---|
October 2022 | 3 |
December 2022 | 3 |
January 2023 | 2 |
February 2023 | 4 |
March 2023 | 4 |
April 2023 | 1 |
May 2023 | 1 |
June 2023 | 2 |
July 2023 | 2 |
August 2023 | 2 |
September 2023 | 2 |
October 2023 | 2 |
November 2023 | 2 |
December 2023 | 2 |
January 2024 | 1 |
February 2024 | 1 |
March 2024 | 2 |
April 2024 | 1 |
May 2024 | 1 |
June 2024 | 2 |
July 2024 | 1 |
August 2024 | 1 |